Vaxcyte

PCVX41

$106.49arrow_drop_down0.64%-$0.69

PCVX41

$106.49

arrow_drop_down0.64%-$0.69

Performance History

Key Stats
Open	$105.73
Prev. Close	$107.29
EPS	-4.69
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	104.50	107.92
52 Week Range	44.20	121.05

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.69

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Vaxcyte (PCVX)

Vaxcyte, Inc. (PCVX) is a biotechnology company that specializes in the development of vaccines for the prevention of infectious diseases. The company's lead product candidate is VAX-24, a pneumococcal conjugate vaccine that is designed to provide protection against pneumococcal disease. Pneumococcal disease is a leading cause of illness and death worldwide, and there is a significant unmet need for an effective vaccine. VAX-24 has shown promising results in clinical trials, and the company is currently conducting a Phase 3 trial to evaluate its safety and efficacy.

In addition to VAX-24, Vaxcyte is also developing a pipeline of other vaccine candidates. This includes VAX-XP, a vaccine for the prevention of infections caused by Staphylococcus aureus, and VAX-CRM, a vaccine for the prevention of infections caused by Group A Streptococcus. The company is dedicated to advancing the field of vaccinology and addressing global health challenges through the development of innovative vaccines.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Grant E. Pickering M.B.A.
Headquarters: San Carlos
Employees: 158
Exchange: NASDAQ

Keep an eye on Vaxcyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Vaxcyte's (PCVX) price per share?

The current price per share for Vaxcyte (PCVX) is $106.49. The stock has seen a price change of -$0.69 recently, indicating a -0.64% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Vaxcyte (PCVX)?

For Vaxcyte (PCVX), the 52-week high is $121.06, which is 13.68% from the current price. The 52-week low is $44.2, the current price is 140.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Vaxcyte (PCVX) a growth stock?

Vaxcyte (PCVX) has shown an average price growth of -2.46% over the past three years. It has received a score of 91 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vaxcyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Vaxcyte (PCVX) stock price performance year to date (YTD)?

As of the latest data, Vaxcyte (PCVX) has a year-to-date price change of 69.19%. Over the past month, the stock has experienced a price change of -4.31%. Over the last three months, the change has been 46.4%. Over the past six months, the figure is 60.38%.

help

Is Vaxcyte (PCVX) a profitable company?

Vaxcyte (PCVX) has a net income of -$402.27M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$468.04M. Furthermore, the EBITDA is -$573.11M.

help

What is the market capitalization of Vaxcyte (PCVX)?

Vaxcyte (PCVX) has a market capitalization of $13.18B. The average daily trading volume is 106.85, indicating the stock's liquidity and investor engagement.

News

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher

VAXCYTE

VAX-31

PNEUMOCOCCAL CONJUGATE VACCINE

PHASE 1/2 STUDY

ADULTS AGED 50 AND OLDER

Sep 2, 2024

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Impetigo Drugs Global Strategic Business Report 2024 - Fusidane Drug Segment is Expected to Reach US$883.5 Million by 2030, with a CAGR of a 5.1%

DIRECTORS AND OFFICERS

Jul 2, 2024

Vaxcyte Appoints John Furey to Board of Directors